Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin
Cancer is a well-known risk factor for venous thromboembolism (VTE), both due to the presence of cancer and to cancer-related interventions. Evidence on what is the best anticoagulation strategy in cancer-associated VTE both in the acute phase and long term is limited. Guidelines recommend treatment with low-molecular-weight-heparin (LMWH) basing the evidence mainly on a single trial that shows that dalteparin is more effective than oral anticoagulation with vitamin K antagonists (VKA) in reducing VTE recurrence with a comparable risk of bleeding . A Cochrane systematic review published in 2014 confirms a reduction of recurrent VTE in patients treated with LMWH compared to VKA (hazard ratio [HR] 0.47; 95% confidence interval [CI] 0.32–0.71, moderate quality of evidence) with no difference in survival and bleeding . A more recent trial comparing full-dose tinzaparin with warfarin for 6 months shows that treatment with full-dose tinzaparin is not associated with a...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with humans and animals performed by any of the authors.
- 2.Ea A, Barba M, Rohilla S et al (2014) Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer (Review). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006650.pub4.www.cochranelibrary.com CrossRefGoogle Scholar